Complete tumor regression, without regrowth, was seen only when cabozantinib was combined with MVA/rF-CEA/TRICOM (Figure 6E) and required the presence of both CD4+ and CD8+ T cells (Figure 6F). Here, CEACAM5 is linked to neoplasm.